International Journal of Molecular Sciences · 2020 · 26 citations · 64 references
MedicineCardiologyPharmacologyGene ExpressionInflammationMolecular PharmacologyCardiac BiomarkersCardiovascular DiseaseCoronary Artery DiseaseEndothelial ActivationEndothelial DysfunctionInflammatory SignalingAtherosclerosis Molecular MechanismsCoronary Artery Disease PharmacotherapyInflammation In Cardiovascular DiseaseNotch Target GenesOxidative Stress In Cardiovascular DiseaseP2y12 Receptor InhibitorsSirtuin 1 RegulationVascular Endothelial Dysfunction
Ticagrelor is a powerful P2Y12 inhibitor with pleiotropic effects in the cardiovascular system. Consistently, we have reported that in patients with stable coronary artery disease (CAD) and concomitant chronic obstructive pulmonary disease (COPD) who underwent percutaneous coronary intervention (PCI), 1-month treatment with ticagrelor was superior in improving biological markers of endothelial function, compared with clopidogrel. The objective of this study was to investigate the mechanisms underlying these beneficial effects of ticagrelor by conducting molecular analyses of RNA isolated from peripheral blood cells of these patients. We determined mRNAs levels of markers of inflammation and oxidative stress, such as RORγt (T helper 17 cells marker), FoxP3 (regulatory T cells marker), NLRP3, ICAM1, SIRT1, Notch ligands JAG1 and DLL4, and HES1, a Notch target gene. We found that 1-month treatment with ticagrelor, but not clopidogrel, led to increased levels of SIRT1 and HES1 mRNAs. In patients treated with ticagrelor or clopidogrel, we observed a negative correlation among changes in both SIRT1 and HES1 mRNA and serum levels of Epidermal Growth Factor (EGF), a marker of endothelial dysfunction found to be reduced by ticagrelor treatment in our previous study. In conclusion, we report that in stable CAD/COPD patients ticagrelor positively regulates HES1 and SIRT1, two genes playing a protective role in the context of inflammation and oxidative stress. Our observations confirm and expand previous studies showing that the beneficial effects of ticagrelor in stable CAD/COPD patients may be, at least in part, mediated by its capacity to reduce systemic inflammation and oxidative stress.
64
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin, Richard C. Becker, Andrzej Budaj et al. · New England Journal of Medicine · 2009 · 7.1K citations · Full text
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
Marc P. Bonaca, Deepak L. Bhatt, Marc Cohen et al. · New England Journal of Medicine · 2015 · 2K citations · Full text
Dopamine Controls Systemic Inflammation through Inhibition of NLRP3 Inflammasome
Yiqing Yan, Wei Jiang, Lei Liu et al. · Cell · 2015 · 1K citations · Full text
From COPD to chronic systemic inflammatory syndrome?
Leonardo M. Fabbri, Klaus F. Rabe · The Lancet · 2007 · 632 citations